title: Early induction of immune resistance against leukemia in lethally total body irradiated mice reconstituted with syngeneic bone marrow cells obtained from previously immunized donor mice.
abstract: BALB/c x DBA/2 F1 (CD2F1) mice were lethally irradiated and reconstituted with syngeneic bone marrow cells (SBMC) obtained from normal or previously immunized (against L1210 lymphatic leukemia) donors. These recipient mice are called TBI + SBMT or TBI + Imm-SBMT mice, respectively. TBI + Imm-SBMT, but not TBI + SBMT mice, were able to develop strong immune resistance against L1210 leukemia, but not against MOPC 104E plasmacytoma, if the immunization procedure (four i.p. injections at weekly intervals of immunogenic L1210 cells) was started as early as 7 days posttransplantation. Incubation of Imm-SBMC with mafosfamide (ASTA Z7654) before grafting abrogated the ability of the recipient mice to develop early resistance against the leukemia. Treatment of Imm-SBMC with monoclonal or polyclonal antibodies plus complement showed that two or three subpopulations of Imm-SBMC were necessary for the transfer of immune information against leukemia: T lymphocytes with phenotype Thy 1.2+, Lyt 1+2-, I-Ad-, macrophages with phenotype Mac-1+, I-Ad-, and probably asialo-GM 1+ cells. Recipient mice immunized against L1210 leukemia before TBI + SBMT do not develop early resistance to the leukemia.
authors.affiliation: Department of Cytophysiology, Medical Center of Postgraduate Education, Warsaw, Poland.
authors.forename: T
authors.initials: T
authors.lastname: Skorski
authors.forename: M
authors.initials: M
authors.lastname: Kawalec
authors.forename: J
authors.initials: J
authors.lastname: Kawiak
mesh_terms: D000818:Animals; D000906:Antibodies / Q000008:administration & dosage; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D016026:Bone Marrow Transplantation / Q000276:immunology* / Q000379:methods; D003165:Complement System Proteins / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D007114:Immunization; D007116:Immunization, Passive; D066298:In Vitro Techniques; D007939:Leukemia L1210 / Q000276:immunology / Q000601:surgery*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010954:Plasmacytoma / Q000276:immunology / Q000601:surgery
chemical_list: D000906:Antibodies; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; C048341:mafosfamide; D003520:Cyclophosphamide; D003165:Complement System Proteins